BRPI0714399B8 - composição farmacêutica líquida oral - Google Patents

composição farmacêutica líquida oral

Info

Publication number
BRPI0714399B8
BRPI0714399B8 BRPI0714399A BRPI0714399A BRPI0714399B8 BR PI0714399 B8 BRPI0714399 B8 BR PI0714399B8 BR PI0714399 A BRPI0714399 A BR PI0714399A BR PI0714399 A BRPI0714399 A BR PI0714399A BR PI0714399 B8 BRPI0714399 B8 BR PI0714399B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
oral liquid
liquid pharmaceutical
composition
oral
Prior art date
Application number
BRPI0714399A
Other languages
English (en)
Inventor
P Hoskovec Gayle
Shield Stephanie
Bubnis William
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38814551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0714399(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0714399A2 publication Critical patent/BRPI0714399A2/pt
Publication of BRPI0714399B1 publication Critical patent/BRPI0714399B1/pt
Publication of BRPI0714399B8 publication Critical patent/BRPI0714399B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição farmacêutica líquida oral; método de tratamento de um mamífero em necessidade de tratamento; e composição farmacêutica oral, aquosa. trata-se de uma composição farmacêutica líquida, oral. a composição compreende fenilefrina e polietileno glicol substancialmente isento de aldeído. a composição tem estabilidade de fenilefrina compatível com a estabilidade exigida para preparações comerciais. a composição pode compreender, opcionalmente, um ou mais agentes ativos adicionais.
BRPI0714399A 2006-07-14 2007-07-11 composição farmacêutica líquida oral BRPI0714399B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/487,120 US20080014274A1 (en) 2006-07-14 2006-07-14 Enhanced stability phenylephrine liquid compositions
US487,120 2006-07-14
US11/487,120 2006-07-14
PCT/US2007/015771 WO2008008364A2 (en) 2006-07-14 2007-07-11 Enhanced stability phenylephrine liquid compositions

Publications (3)

Publication Number Publication Date
BRPI0714399A2 BRPI0714399A2 (pt) 2013-03-12
BRPI0714399B1 BRPI0714399B1 (pt) 2020-11-17
BRPI0714399B8 true BRPI0714399B8 (pt) 2021-05-25

Family

ID=38814551

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714399A BRPI0714399B8 (pt) 2006-07-14 2007-07-11 composição farmacêutica líquida oral

Country Status (26)

Country Link
US (1) US20080014274A1 (pt)
EP (2) EP2351554B1 (pt)
JP (1) JP2009543777A (pt)
KR (2) KR20140088234A (pt)
CN (2) CN101500539A (pt)
AR (1) AR061985A1 (pt)
AU (1) AU2007272961B2 (pt)
BR (1) BRPI0714399B8 (pt)
CA (1) CA2657611A1 (pt)
CO (1) CO6180496A2 (pt)
EC (1) ECSP099072A (pt)
ES (2) ES2537761T3 (pt)
HK (1) HK1205933A1 (pt)
HU (2) HUE025790T2 (pt)
IL (1) IL196447A (pt)
MX (1) MX2009000530A (pt)
NZ (1) NZ574148A (pt)
PE (1) PE20081003A1 (pt)
PL (2) PL2040672T3 (pt)
PT (2) PT2040672E (pt)
RU (1) RU2468787C2 (pt)
SG (2) SG10201408522UA (pt)
TW (1) TW200812640A (pt)
UY (1) UY30484A1 (pt)
WO (1) WO2008008364A2 (pt)
ZA (1) ZA200900315B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
CN104161736A (zh) * 2006-06-01 2014-11-26 Msd消费保健品公司 包含去氧肾上腺素的缓释药物制剂
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
CA2653950A1 (en) * 2006-06-01 2007-12-13 Schering Corporation Phenylephrine pulsed release formulations and pharmaceutical compositions
JP5121824B2 (ja) * 2006-06-01 2013-01-16 メルク・シャープ・アンド・ドーム・コーポレーション フェニレフリンの徐放のための薬学的組成物
MX2009013054A (es) * 2007-06-01 2010-01-15 Schering Plough Healthcare Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US8518439B2 (en) * 2008-12-03 2013-08-27 Novartis Ag Liquid therapeutic composition
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
CA2802362C (en) * 2010-06-11 2017-11-21 Gm Pharmaceuticals, Inc. Pharmaceutical compositions for alleviating upper respiratory and oral-pharyngeal congestion
KR20140012029A (ko) 2010-10-21 2014-01-29 알티유 파머수티컬즈, 엘엘시 즉시 사용가능한 케토로락 제제
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
EP2961377B1 (en) * 2013-02-28 2020-03-18 PF Consumer Healthcare 1 LLC Enhanced stability of novel liquid compositions
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
JP5918895B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤
BR112017025527A2 (pt) * 2015-05-29 2018-08-07 Kiel Laboratories Inc preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe.
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US20180055938A1 (en) * 2016-09-01 2018-03-01 The Procter & Gamble Company Medication With Improved Taste And Sensory Experience
CN109789101A (zh) 2016-09-26 2019-05-21 宝洁公司 延长缓解剂型
CN110115708A (zh) * 2018-02-07 2019-08-13 保瑞药业股份有限公司 乙酰胺酚及曲马多共溶复方止痛口服液
CA3100314A1 (en) 2018-05-16 2019-11-21 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN108434097A (zh) * 2018-06-22 2018-08-24 南京济群医药科技股份有限公司 一种稳定的含盐酸曲普利啶口服溶液剂及其制备方法
CN109010341A (zh) * 2018-10-29 2018-12-18 南京济群医药科技股份有限公司 一种含有氢溴酸右美沙芬的复方口服溶液及其制备方法
WO2020210723A1 (en) 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
MA58173B1 (fr) 2019-12-23 2024-03-29 Nutra Essential Otc S L Composition liquide comprenant de l'ibuprofène et de la phényléphrine
WO2021150747A1 (en) * 2020-01-22 2021-07-29 Nevakar Inc. Phenylephrine hydrochloride compositions and containers
CN111773203B (zh) * 2020-05-15 2024-11-26 北京博智绿洲医药科技有限公司 一种包含盐酸去氧肾上腺素组合物的制备工艺
CN111803452B (zh) * 2020-07-08 2026-02-06 北京博智绿洲医药科技有限公司 一种包含盐酸去氧肾上腺素组合物的泡腾颗粒剂制备工艺
CN114533664B (zh) * 2022-01-29 2023-03-31 江苏广承药业有限公司 一种氢溴酸右美沙芬和愈创木酚甘油醚复方口服液体制剂
WO2026015096A1 (en) * 2024-07-09 2026-01-15 Humanis Sağlik A.Ş. Paraben free syrup compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515781A (en) * 1967-10-12 1970-06-02 Johnson & Johnson Cold capsule
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
US6287597B1 (en) 1999-03-12 2001-09-11 Carter-Wallace, Inc. Antihistaminic/decongestant compositions
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
WO2003011306A1 (en) 2001-07-31 2003-02-13 Wyeth Sucralose formulations to mask unpleasant tastes
US6462094B1 (en) * 2001-08-22 2002-10-08 Medpointe Healthcare Inc. Decongestant/expectorant compositions
US6509492B1 (en) * 2001-08-31 2003-01-21 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
US20030060422A1 (en) * 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US20040132827A1 (en) 2001-10-26 2004-07-08 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20050267222A1 (en) * 2002-10-22 2005-12-01 Dainippon Pharmaceutical Co. Ltd. Stabilized composition
US6979689B2 (en) 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
JP2004300138A (ja) * 2003-03-18 2004-10-28 Takeda Chem Ind Ltd 安定化された経口固形製剤
US20050152967A1 (en) 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
DE10358213A1 (de) 2003-12-12 2005-07-28 Clariant Gmbh Polyethylenglykol und dessen Herstellung
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006022996A2 (en) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20060148837A1 (en) 2005-01-04 2006-07-06 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
US20070160689A1 (en) * 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness

Also Published As

Publication number Publication date
PE20081003A1 (es) 2008-07-13
KR20140088234A (ko) 2014-07-09
HK1128886A1 (en) 2009-11-13
TW200812640A (en) 2008-03-16
AU2007272961B2 (en) 2011-07-28
BRPI0714399B1 (pt) 2020-11-17
CN104546671A (zh) 2015-04-29
EP2040672B1 (en) 2015-04-01
MX2009000530A (es) 2009-01-27
PT2040672E (pt) 2015-07-02
RU2009101295A (ru) 2010-08-27
JP2009543777A (ja) 2009-12-10
ES2537761T3 (es) 2015-06-11
IL196447A0 (en) 2009-09-22
CN101500539A (zh) 2009-08-05
CO6180496A2 (es) 2010-07-19
EP2040672A2 (en) 2009-04-01
PL2040672T3 (pl) 2015-07-31
ES2550036T3 (es) 2015-11-04
SG173354A1 (en) 2011-08-29
WO2008008364A2 (en) 2008-01-17
KR20090040334A (ko) 2009-04-23
PL2351554T3 (pl) 2016-01-29
CA2657611A1 (en) 2008-01-17
BRPI0714399A2 (pt) 2013-03-12
AR061985A1 (es) 2008-08-10
HUE025694T2 (hu) 2016-04-28
UY30484A1 (es) 2008-02-29
AU2007272961A1 (en) 2008-01-17
WO2008008364A3 (en) 2008-05-22
HUE025790T2 (hu) 2016-05-30
HK1205933A1 (en) 2015-12-31
NZ574148A (en) 2012-07-27
RU2468787C2 (ru) 2012-12-10
ZA200900315B (en) 2009-12-30
IL196447A (en) 2015-06-30
ECSP099072A (es) 2009-02-27
EP2351554B1 (en) 2015-09-09
PT2351554E (pt) 2015-11-02
US20080014274A1 (en) 2008-01-17
SG10201408522UA (en) 2015-02-27
EP2351554A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112014027039A2 (pt) formulação farmacêutica tópica não aquosa; uso de formulação farmacêutica não aquosa; formulação não aquosa; e método
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
NO20084111L (no) Antimikrobielle sammensetninger samt fremgangsmater for festekatetere
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
GT201400285A (es) Formulacion de anticuerpos
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
CR20110110A (es) Composicion farmaceutica
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
MX2009005696A (es) Nanoparticulas magneticas para la aplicacion en hipertermia, preparacion de las mismas y uso en constructos que tienen una aplicacion farmacologica.
BR112015000203A2 (pt) formulações de etanercept que exibem redução marcada em partículas sub-visíveis
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
BR112014031841A2 (pt) formulação farmacêutica
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: WYETH LLC (US)

B25G Requested change of headquarter approved

Owner name: WYETH LLC (US)

B25A Requested transfer of rights approved

Owner name: PF CONSUMER HEALTHCARE 1 LLC (US)